The outcome of the adaptive immune response is determined by the integration of both positive and negative signals, respectively, induced upon the triggering of co-signaling receptors. One of them, programmed cell death 1 (PDCD1/PD-1) has largely been shown to be involved in the negative regulation of T-cell activation. However, PD-1 is also expressed on human B cells, and its role(s) in the process of human B-cell activation remains uncertain thus far. In this study, we describe the expression of PD-1 on the major human B-cell subsets isolated from peripheral blood and lymph nodes. We showed that PD-1 was expressed on naive B cells, was differentially expressed on peripheral 
Introduction
B lymphocytes are the source of the humoral immune response against a given antigen. Understanding their activation process is of major importance to develop effective vaccine-based strategies, without autoimmunity. As members of the adaptive immune system, B cells need to receive at least two signals to engage their activation program. The first signal comes from the recognition of their cognate antigen through the B-cell receptor (BCR). The second signal depends on the engagement of activating and inhibitory co-receptors that, when triggered during an immune reaction, induce a positive or a negative cell signaling pathway, respectively. The integration of these opposite signals determines the extent of B-cell activation and orientates B-cell fate. The CD28/B7 family is one of the most important families of co-receptors that orchestrates and regulates the adaptive immune response. In addition to the widely studied activator co-receptors (CD28 and ICOS), the CD28/B7 family contains three co-inhibitory receptors: cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and B-and T-lymphocyte attenuator (BTLA) (1) (2) (3) . In addition to their known regulatory role in T-lymphocyte activation, these co-receptors are known to be involved in multiple other aspects of the adaptive immune system, notably lymphocyte differentiation, maturation, adhesion, chemotaxis and cytokine production (2, (4) (5) (6) .
PD-1 (CD279) is a type-I transmembrane protein composed of one immunoglobulin superfamily domain, a transmembrane domain and an intracellular domain containing an immuno-receptor tyrosine-based inhibitory motif and an immuno-receptor tyrosine-based switch motif (2, 7) . PD-1 was initially described as an immunoglobulin-superfamily member over-expressed upon programmed cell death (1) . The activation of T cells, B cells and monocytes induces PD-1 expression (8) . And, indeed, it has now become clear that the primary function of PD-1 is to attenuate the immune response. Indeed, PD-1 was shown to limit the progression of diabetes in non-obese diabetic mice (9) , cytokine production and lymphocyte proliferation by stopping T lymphocyte in the G0/ G1-phase (10) . PD-1 has two known ligands (PD-Ls): PD-1 ligand 1 (PD-L1, B7-H1 or CD274) (11, 12) and programmed death ligand 2 (PD-L2, B7-DC, CD273) expressed in normal conditions (13, 14) . They compete for PD-1 binding but differ in their molecular mechanisms of interaction with this receptor (15) . PD-L2 is expressed in far fewer cell types than PD-L1. PD-L2 is expressed on most antigen-presenting cells (APC) (14, 16) and on activated CD4 + T cells (17) . In contrast, PD-L1 is broadly expressed not only in hematopoietic, such as B and T lymphocytes, dendritic cells and macrophages, but also in non-hematopoietic cells, notably endothelial, epithelial, muscular and trophoblastic cells (18) . Functionally, in the context of HIV-positive patients, the blocking of PD-1/PD-L1 interaction enhances the proliferation of T cells and restores their cytotoxic function. The PD-1/PD-L1 complex thus now appears as a new interesting therapeutic option in the treatment of HIV (19) . Not surprisingly, as virus-infected and malignant cells often shared similar strategies to escape from the immune system, recent reports show that PD-1 is also involved in a mouse model of solid tumors (20) . In human, PD-L1 and PD-L2 are expressed in several tumors and are often associated with the prognosis (21) (22) (23) (24) (25) (26) .
The roles of PD-1 on T-cell responses have widely been studied thus far. However, the implication of PD-1 triggering on human B-cell responses still remained poorly documented despite the obvious effect observed in PD-1 −/− mice. Indeed those mice exhibited moderate splenomegaly and increased B-cell proliferation after stimulation with anti-IgM antibodies in vitro, clearly pointing at PD-1 as a negative regulator of B-cell proliferation, differentiation and isotype class switch (4). In the mouse, it was demonstrated that this inhibitory effect was effective through the triggering of the inhibitory BCR signaling pathway [SYK (spleen tyrosine kinase), PI3K (phosphatidylinositol 3 OH kinase), PLC-γ2 (phospholipase Cγ2) and ERK (extracellular signal-regulated kinase)] by PD-1 (27) .
In this study, we attempted to examine the function of PD-1 on human B-cell activation. We monitored PD-1 expression on different B-cell subsets and during ex-vivo B-cell activation. Such an approach was ineluctable to establish how B-cells are activated, as we know that different B-cells subsets are preferentially involved in various immunological responses and because the expression of CD28/B7 family members is usually highly regulated during the B-cell activation process, and notably during the germinal center (GC) reaction. We thus showed a basal level of PD-1 expression on all resting B-cell subsets from the blood and non-GC-B-cell subsets from lymphoid organs, with a clear up-regulation during B-cell activation. We next demonstrated that preventing PD-1 engagement with both its ligands enhances B-cell cytokine production and proliferation. Finally, we identified that PD-1 tightly clustered with the BCR upon B-cell activation, suggesting a major role of PD-1 in the regulation of the B-cell activation through co-signaling. 
Methods

Peripheral blood cells
Lymph node cells
Cells were obtained from patients treated at the Institut Paoli Calmettes, who were prospectively recruited on diagnosis. Lymph nodes were sampled during surgical diagnostic procedures and were extemporaneously treated. The study was approved by the institutional review boards of the Institut Paoli Calmettes. Patients provided informed consent in accordance with the Declaration of Helsinki. Mononuclear cells were obtained by crushing fresh tissue samples in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum. After additional washes, cells were counted and re-suspended in PBS and 2% BSA for fluorescent staining.
Affymetrix
Public affymetrix U133 + 2 data sets from purified resting, naive, GC and memory B cells and plasmocytes were retrieved from the public GEO data sets GSE12195 (http:// www.ncbi.nlm.nih.gov/gds). We used robust multichip average (RMA) with the non-parametric quantile algorithm as normalization parameter. RMA was applied to the raw data, and quantile normalization and Loess' correction were done in R using Bioconductor and associated packages. The probe set corresponding to CD28 (206545_at), CTLA-4 (236341_at), ICOS (210439_at), PD-1 (207634_at) and BTLA (236226_at) were retrieved from the normalized data sets and the corresponding log values were linearized for graphical representation.
Generation of an anti-human PD-1 mAb and Fab fragmentation
A mAb recognizing PD-1 (clone 3.1) was generated by immunization of BALB-c mice with the respective recombinant human Fc-IgG1 fusion proteins. After fusion, the hybridoma supernatants were screened for staining of transfected cells and for lack of reactivity with untransfected cells. Fab fragmentation was performed using papain with ImmunoPure Fab Preparation Kit according to the manufacturer's protocol (Pierce).
Flow cytometry
PE-conjugated-anti-IgD, FITC-conjugated-anti-CD27, 7-aminoactin-D staining solution and isotypic controls were purchased from BD Biosciences, APC Alexa Fluor 780-conjugated-anti-CD19 from eBioscience and PC5-conjugated-anti-CD38 and FITC-conjugated-anti-CD80 from Beckman Coulter. Anti-PD-1 (clone 3.1) antibody was produced and conjugated in our laboratory with Alexa Fluor ® 647 Protein Labeling Kit (Molecular Probes InvitroGen). For assessment of surface molecules, cells were labeled with predetermined optimal antibody concentrations according to the manufacturer's staining protocol. Data acquisition was performed on a Canto II ® flow cytometer and analyzed using FACS Diva Software (BD Biosciences).
Immunohistochemical analysis
For double-IHC stainings on reactive lymph nodes, we selected samples from a group of PD-1-positive tissues. About 5 µm thick formalin-fixed paraffin-embedded tissue sections were cut and double stained for PD-1 (clone 3.1) and PAX5 (from DakoCytomation, Glosturp, Denmark). Detection of the first antigen was performed by a three-stage mouse peroxidase-antiperoxidase technique, and detection of PAX5 was performed by the APAAP (alkaline phosphatase-antialkaline phosphatase) procedure using the DAKO kit according to the supplier's recommendation.
Immunofluorescence
Cover slips were coated with poly-l-lysine (Sigma-Aldrich) for 30 min. Sorted B cells grown on cover slips were fixed in methanol at -20°C for 6 min and rinsed with PBS. After blocking with PBS and 5% BSA, cells were incubated with primary antibodies, diluted in PBS-BSA, for 30 min. After washing in PBS and 0.1% Tween 20, primary antibodies were detected using anti-immunoglobulin secondary antibodies conjugated to cyanine 5 obtained from Jackson Laboratories or Alexa Fluor (Alexa Fluor 488) from InvitroGen. Nuclei were stained with 250 ng/ml of DAPI (Roche Diagnostics). Cells were mounted in Prolong Gold anti-fade reagent (InvitroGen) and examined on an LSM-510 Carl Zeiss confocal microscope with a ×63 NA1.4 Plan Apochromat objective. Optical sections were projected with LSM Software (Zeiss).
Blockade of PD-1/PD-Ls
About 1 × 10 5 B cells were activated by 2 µg/ml of ODN 2006 and CpG-B (InvivoGen) and were incubated for 5 days with 10 µg/ml of recombinant human PD-L1 Fc or PD-L2 Fc chimeric fusion proteins (R&D Systems) or with control Fc fusion protein (mutated Thy-1-Fc, Alexis Biochemicals). The blocking of receptor-ligand interactions were performed using 10 µg/ ml of home-made anti-PD-1 (Fab 2, clone 3.1) antibodies.
ELISA tests
Production of IL-6, IL-8 and MIP-1β was measured using ELISA kits (R&D Systems) according to the manufacturer's instructions.
Proliferation assays
Cells were diluted in PBS at 1 × 10 7 cells/ml and labeled for 10 min at 37°C with 2.5 µM carboxyfluoresceine diacetate (Molecular Probes InvitroGen) for the assessment of B-cell proliferation. B cells were cultured in the presence of 2 µg/ml CpG-B with or without 10 mg/ml anti-PD-1 antibody for 5 days at 37°C.
Statistical analysis
Results are expressed as median ± SEM. Statistical analyses were evaluated using the two-tailed non-parametric unpaired Mann-Whitney t-test when comparing the two groups of different donors or with the non-parametric paired Wilcoxon t-test when comparing same donors in different conditions. All tests were performed with the GraphPad Prism ® statistical analysis program. Only P values < 0.05 were considered significant.
Results
PD-1 is differentially expressed on B-cell subsets
Thus far, PD-1 expression during human B-cell differentiation has been poorly studied. We thus quantified PD-1 transcripts in non-activated peripheral B cells. First, when compared with other known co-receptors from the CD28/B7 family, the transcript of PD-1 was constitutively present, as for the other inhibitory co-receptors BTLA and, to a lesser extent, CTLA-4, whereas the transcripts of co-activator receptors (CD28 and ICOS) were not detected at baseline (Fig. 1A) .
As for the transcript, PD-1 was constitutively expressed at the surface of non-activated circulating B cells. We next wondered whether B-cell subsets found in the peripheral blood of healthy individuals would differentially regulate their expression of PD-1. Two memory B-cell subsets have been described thus far: the classical isotype-switched memory and the so-called "IgM memory" B cells. Classically, CD27
+ memory B cells arise from GC reactions and have gone through immunoglobulin class-switching and somatic hypermutation.
Recent studies tend to demonstrate that peripheral blood IgM memory B cells are unswitched, retain expression of both IgM and IgD, and likely arise from the splenic marginal zone (MZ). Such B cells nevertheless demonstrate somatic immunoglobulin hypermutation and contribute to rapid immunological memory. Notably, they are among the first responders against bacterial infection (28) (29) (30) (31) . In humans, we identified the naive and the two memory B-cell subsets based on the combination of the IgD and the CD27 markers, CD27 being expressed on most memory B cells (29, 32) (Supplementary  Fig. 1A , available at International Immunology Online). We observed that all B-cell sub-populations expressed PD-1. Nevertheless, IgM memory displayed a higher expression of PD-1 compared with naive (P = 0.001) and switched-memory (P = 0.002) B cells ( Figure 1B and Supplementary Fig. 1B , available at International Immunology Online). Such variability suggested that PD-1 might even be more important in the regulation of B-cell activation under certain conditions, i.e. in rapidly activated MZ-derived memory B cells.
We next sought to compare our results to PD-1 expression on T-cell subsets. According to previous studies, others and we have shown that PD-1 is expressed on activated CD4 + T cells and has a strong expression on effector memory T cells (EM) (33) . Here, we showed that PD-1 expression was significantly higher on naive B cells as compared with naive T cells (P = 0.0299) (Fig. 1B) , suggesting that PD-1 might play a major role in the regulation of naive B-cell activation. This difference was not significant anymore between memory cells (central memory and EM T cells) from the B and T lineages, all expressing strong levels of PD-1 (Fig. 1B) that were previously shown, in the particular case of T cells only, to negatively control memory T cells re-activation (33) .
We next wondered if PD-1 expression was regulated during B-cell activation, i.e. in an inflammatory context such as Supplementary  Fig. 1C and D, available at International Immunology Online), we thus analyzed PD-1 expression on naive and memory B cells (mantle and MZ B cells) from reactive lymph nodes and not surprisingly found similar profiles to those respectively reported in peripheral blood. However, both the transcript and the protein expression of PD-1 were drastically decreased on GC-B cells as compared with other B-cell sub-populations (Fig. 1C and Supplementary Fig. 2A , available at International Immunology Online). This observation was confirmed using a double immunohistochemical staining showing the mutually exclusive expression of PAX5 (staining the GC-B cells in brown) and PD-1 high expression (in red) restricted to GC-T cells ( Supplementary Fig. 2B , available at International Immunology Online). This major observation suggests that PD-1 expression needs to be turned off in GCs to allow B-cell proliferation and other memory B-cell selection process to occur.
Function of PD-1 on human B cells
Altogether our observations showed that PD-1 was strongly expressed on all B-cell subsets, notably on IgM memory B cells, but its expression was lost upon B-cell entry in the GC, before being re-acquired upon exit. These results underlay a major role of PD-1 in controlling B-cell activation, but not during the BCR affinity maturation process that will generate long-term memory B cells.
PD-1, PD-L1 and PD-L2 expression is increased during B-cell activation
We next examined the kinetics of PD-1 expression on B cells using two different activation pathways: the BCR pathway (by stimulating with anti-IgM mAb) and TLR9 pathway (CpG-B stimulation); both activation methods were pertinent regarding the expression of PD-1 on the different B-cell subsets as described in the above section. The analysis was performed as depicted in Fig. 2A . For 5 days, PD-1 expression was maintained in the absence of stimulation while its expression progressively increased under the stimulation by the TLR9 agonist CpG-B (Fig. 2A) . This increase was significant as soon as 48 h of activation with CpG-B. The specific activation through the BCR (anti-IgM stimulation) showed a weak tendency to PD-1 up-regulation, albeit it remained not significant at 96 h (Fig. 2B) .
In parallel, we observed that most B-cell activation pathways induced the progressive up-regulation of PD-1 ligands, PD-L1 and PD-L2. The increase was more pronounced for PD-L1, and occurred as soon as 24 h after activation with both anti-IgM and CpG-B (Fig. 2C and D and Supplementary  Figure 3 , available at International Immunology Online). The up-regulation of PD-1 ligands suggested that they could act on other B cells in "cis," as it was already demonstrated on T cells for another couple of inhibitory co-receptors, namely BTLA/HVEM (34).
PD-1 clusters with the BCR upon B-cell activation
As a co-receptor involved in B-cell activation, we next investigated the distribution of PD-1 on the B-cell surface during B-cell activation. We used CD19 as a surrogate marker that was recently shown to be important to propagate BCR micro-signalosomes spreading and B-cell activation (35) . We monitored PD-1 localization during BCR-triggering and observed that PD-1 was recruited at the BCR as soon as 15 min after the beginning of the stimulation and maintained at least 30 min after (Fig. 3) , potentially interfering with the BCR signal transduction pathway.
We thus decided to look at the effective functional consequences of PD-1 on B-cell functions.
PD-1/PD-Ls blockade restore IL-6 production and B-cells proliferation
First, we showed that both PD-1 triggering with recombinant PD-L1 and PD-L2 decreased IL-6 synthesis by activated B cells. This effect was reversed when blocking PD-1 interacts with its ligands, using the Fab' part as an antagonist PD-1 mAb (33) . The synthesis of other chemokines (MIP-1β and IL-8) and B-cells survival were not affected by the effective interactions between PD-1/PD-Ls (Fig. 4A and data not  shown) . However, we did observe a major effect on B-cells proliferation that was clearly enhanced in presence of PD-1 blocking antibody, namely PD-L1-Fc and/or PD-L2-Fc recombinant antibodies (Fig. 4B ). This effect is perfectly coherent with the previous observation showing that PD-1 was switched off in the GC, certainly to allow B-cell proliferation as part of the high-affinity memory B-cells generation process. We also investigated the effect of PD-1 on B-cells activation and showed that the percentage of B cells expressing the activation markers CD80 and CD86 was highly increased in the presence of these antibodies (Fig. 4C) .
In all cases, we noticed individual effects of both PD-L1 and PD-L2, but no additive or synergic effect, suggesting that PD-L1 and PD-L2 might compete for PD-1 receptors ( Supplementary Fig. 4A and B, available at International Immunology Online). Furthermore, we observed a certain redundancy in PD-L1-and PD-L2-mediated functions, at least regarding those tested thus far.
Discussion
To our knowledge, this is first report addressing the expression and the functional role of PD-1 on human B cells. To understand how PD-1 could affect B-cell functions, we first examined the expression of PD-1 on different B-cell subsets.
In peripheral blood, we showed that PD-1 was expressed on all B-cell subsets, including naive cells, and was particularly strong on IgM memory B cells. IgM memory B cells are generated in T-cell independent reactions and seem to re-circulate from the spleen MZ (28, 30, 32) . These cells are important to elicit rapid B-cell response, producing mostly unmutated immunoglobulin. PD-1 might thus be a major checkpoint of such T-cell independent B-cell activation and immunoglobulin 
Function of PD-1 on human B cells 133
production. In addition, the PD-1-PD-L1 pathway regulates mouse B-cell survival in GCs (36) .
Conversely, we showed that PD-1 was specifically down-regulated on GC B cells. We and others have previously observed that other B7/CD28 family members showed a similar pattern of expression, like BTLA7 (37, 38) . These data were confirmed at the transcriptional level ( Supplementary Fig. 5 , available at International Immunology Online) and emphasized the putative role of PD-1, and potentially other co-inhibitory receptors, as major regulatory molecules of B-cell activation and/or entry into GCs. Indeed these co-inhibitory molecules were strictly decreased in the GC-related activation process, i.e. during proliferation, maturation, selection, class switch and somatic hypermutation. Here, we have been able to show that PD-1 could negatively regulate B-cell activation, proliferation and IL-6 production (a major cytokine supporting B-cell growth), i.e. major functions involved in the GC reactions. But it is not excluded that PD-1 modulation might also play a role in entry into GCs, as all B cells from PD-1 −/− mice enter the GC, are hypermutated and the immunoglobulin is class-switched. Of note, we tested the effect of anti-PD-1 antibody and the blockade of PD-1/PD-Ls pathways on immunoglobulin production, but we did not observe any effect on immunoglobulin class-switch on activated B cells (data not shown). One plausible explanation might simply be that PD-1 has to be down-regulated in the presence of or in response to a given signal, to allow class switch recombination events to happen, a condition that we have not reproduced in vitro.
PD-1 was immediately re-acquired upon GC exit; and now, B cells became high-affinity memory B cells, reinforcing its role as a guardian of uncontrolled activation.
Besides, we showed a progressive up-regulation of the expression of PD-1 and its ligands on CpG-and IgM-mediated B-cell activation, suggesting that these molecules certainly also have a role in the regulation of B-cell activation and highlight their importance in the prevention against inflammatory and autoimmune diseases.
Furthermore, we noticed that PD-L1 and PD-L2 seemed to compete for PD-1 binding, but it was reported that they differed in their molecular mechanisms of interaction with PD-1. These molecules bind PD-1 with comparable affinities, but striking differences were observed at the level of the association and dissociation characteristics (15) . Notably, PD-L1 needs a conformation change for an efficient binding with PD-1.
Despite these observations, we did not show any difference between PD-1/PD-L1 and PD-1/PD-L2 blockade; neither did we observe any additive effect when using a combination of the two blocking antibodies, confirming the competition between the two ligands. The quantity of available PD-1 receptors at the B-cell surface might be a limiting factor controlling B-cell activity, which would be coherent with the variable level of PD-1 expressed on the different B-cell subsets. Furthermore, it was recently reported that the balance might be disturbed by the introduction of a third actor, which is CD80 (B7-H1) and could interact with PD-L1. As for PD-1, CD80 is also expressed by B cells, dendritic cells and macrophages, and it has itself three known ligands: another inhibitory co-receptor CTLA-4 (39, 40) , an activating co-receptor CD28 and most recently PD-L1 (41) . A new ligand-receptor complex complicates the interpretation of the whole picture. This reflects the complexity of the human B-cell activation system, with a balance between "GO" and "STOP" signals involving the engagement of different co-receptors, available at a given time. B-cell 
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functions are thus regulated by a complex hyperdynamic system: a given co-signaling pathway can thus have different effects on different cell types, in different activation state, in different cellular or anatomical compartments, and might result in synergistic or antagonistic effects that make it difficult to predict the final effect of a particular pathway in a specific cell type. It is thus important to have a global view of the system, which we will consider in our future investigations.
On a functional point of view, this study provides evidence that PD-1 is a new inhibitory molecule of human B-cell activation. In particular, we showed that PD-1 clustered with the BCR in response to a stimulus, and we reported, as previously mentioned, numerous inhibitory effects on the B-cell activation process. Interestingly, PD-1 signals did not prevent CD40L signals (data not shown). The expression and the role of negative regulators of immune functions are essential aspects that aid our understanding of the basis of B-cell responses during the course of various de-regulated immune disease. Indeed, some diseases generating irreversible damage occur because of exacerbated immune responses, such as RSV (respiratory syncitial virus) infection in young children, allergic diseases or autoimmune disease. It is thus of primary importance to provide new molecules able to control this overreacting inflammatory response at multiple levels (42) . Here, we showed that PD-1 is another inhibitor of the Toll like receptor (TLR)-ligand-mediated activation of B cells. The PD-1/PD-Ls pathway might be targeting other aspects of TLR-mediated inflammation and should be investigated in different inflammatory situations.
Conversely, if the PD-1/PD-Ls pathway inhibits the B-cell activation, these molecules might also be of primary importance in the development of effective anti-tumor immunotherapy. Indeed, as PD-L1 is expressed in several tumors, is generally associated with a bad prognosis, and given that the disruption of PD-1/PD-L1 interactions by infusion of blocking antibodies enhanced immune-mediated anti-tumor responses, the blocking of the PD-1/PD-L1 pathway should now be considered as an attractive field in cancer immunotherapy (43) . Currently, two humanized anti-PD-1 antibodies (MDX-1106, Medarex and CT-011, Cure Tech) have been evaluated in phase I clinical trials in patients with solid and hematological malignancies (44) .
Berger et al. showed the CT-011 anti-PD-1 antibody to be safe and well tolerated in population of patients with hematological malignancies (44) . Clinical benefit was even observed in 33% of the patients and one patient with follicular lymphoma is in complete remission. These studies suggest that PD-1 can indeed play a crucial role in malignant B-cell development. However, the authors have studied the behavior of the CD4, CD8 and CD69 markers, but there are still no available data on the B-cell activation status after anti-PD-1 injection, which is something that has to be taken into account in the future investigations considering the tight cooperation existing between B and T lymphocytes and especially when studying lymphoma.
The remarkable progress in identifying these new members of the CD28/B7 family, together with their signal transduction pathways, has opened up exciting novel molecular targets for the treatment of both cancers and inflammatory diseases.
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